Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide

Antonina Giammanco; Davide Noto; Maurizio Averna; Angelo Baldassare Cefalu'

Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide

Antonina Giammanco, Davide Noto, Maurizio Averna, Angelo Baldassare Cefalu'

Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”

Risultato della ricerca: Article › peer review

3 Citazioni (Scopus)

Abstract

Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the microsomal triglyceride transfer protein (MTP) approved as a novel drug for the management of homozygous familial hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine.

Lingua originale	English
pagine (da-a)	3773-3783
Numero di pagine	11
Rivista	Current Medicinal Chemistry
Volume	27
Stato di pubblicazione	Published - 2020

All Science Journal Classification (ASJC) codes

???subjectarea.asjc.1300.1303???
???subjectarea.asjc.1300.1313???
???subjectarea.asjc.3000.3004???
???subjectarea.asjc.3000.3002???
???subjectarea.asjc.1600.1605???

Altri file e collegamenti

OA Link

Cita questo

@article{5c1eb886ae89407b8f5bef718ee8865c,

title = "Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide",

abstract = "Lomitapide (Juxtapid{\textregistered} in US and Lojuxta{\textregistered} in Europe) is the first developed inhibitor of the microsomal triglyceride transfer protein (MTP) approved as a novel drug for the management of homozygous familial hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine.",

keywords = "HoFH – Lomitapide – LOWER Registry – MTP inhibition – MTP SNPs, HoFH – Lomitapide – LOWER Registry – MTP inhibition – MTP SNPs",

author = "Antonina Giammanco and Davide Noto and Maurizio Averna and Cefalu', {Angelo Baldassare}",

year = "2020",

language = "English",

volume = "27",

pages = "3773--3783",

journal = "Current Medicinal Chemistry",

issn = "0929-8673",

publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide

AU - Giammanco, Antonina

AU - Noto, Davide

AU - Averna, Maurizio

AU - Cefalu', Angelo Baldassare

PY - 2020

Y1 - 2020

N2 - Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the microsomal triglyceride transfer protein (MTP) approved as a novel drug for the management of homozygous familial hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine.

AB - Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the microsomal triglyceride transfer protein (MTP) approved as a novel drug for the management of homozygous familial hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine.

KW - HoFH – Lomitapide – LOWER Registry – MTP inhibition – MTP SNPs

UR - http://hdl.handle.net/10447/387950

M3 - Article

SN - 0929-8673

VL - 27

SP - 3773

EP - 3783

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

ER -

Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide

Abstract

All Science Journal Classification (ASJC) codes

Altri file e collegamenti

Fingerprint

Cita questo